Table 2. Comparison of clinical characteristics and immunohistochemical expression of HE4 and Integrin β5 in 92 cases of epithelial ovarian cancer.
| Characteristics | N | Group | P | HE4 | Integrin β5 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sensitive | Resistant | − | + | ++ | +++ | P | − | + | ++ | +++ | P | |||
| Age group, n(%) | ||||||||||||||
| ≤60 | 74 | 47(83.9) | 27(75.0) | 0.292‡ | 16 | 17 | 17 | 13 | 0.065 | 13 | 24 | 19 | 7 | 0.161 |
| >60 | 18 | 9(16.1) | 9(25.0) | 1 | 13 | 9 | 6 | 11 | 5 | 10 | 3 | |||
| FIGO Stage, n(%) | ||||||||||||||
| I-II | 31 | 27(48.2) | 4(11.1) | <0.001*‡ | 10 | 7 | 9 | 5 | 0.081 | 11 | 8 | 8 | 4 | 0.435 |
| III-IV | 61 | 29(51.8) | 32(88.9) | 7 | 23 | 17 | 14 | 13 | 21 | 21 | 6 | |||
| Differentiation, n(%) | ||||||||||||||
| Well | 14 | 10(17.9) | 4(11.1) | 0.318‡ | 5 | 2 | 4 | 3 | 0.435 | 4 | 3 | 5 | 2 | 0.866 |
| Moderate | 43 | 28(50.0) | 15(41.7) | 8 | 15 | 13 | 7 | 12 | 12 | 15 | 4 | |||
| Poor | 35 | 18(32.1) | 17(47.2) | 4 | 13 | 9 | 9 | 8 | 14 | 9 | 4 | |||
| Pathological Subtype, n(%) | ||||||||||||||
| Serous carcinoma | 60 | 36(64.3) | 24(66.7) | 0.815‡ | 8 | 22 | 16 | 14 | 0.251 | 17 | 16 | 19 | 8 | 0.460 |
| Non-serous carcinoma | 32 | 20(35.7) | 12(33.3) | 9 | 8 | 10 | 5 | 7 | 13 | 10 | 2 | |||
| Lymph node metastasis, n(%) | ||||||||||||||
| No | 63 | 43(76.8) | 20(55.6) | 0.032*‡ | 14 | 21 | 17 | 11 | 0.449 | 19 | 18 | 18 | 8 | 0.393 |
| Yes | 29 | 13(23.2) | 16(44.4) | 3 | 9 | 9 | 8 | 5 | 11 | 11 | 2 | |||
| Residual tumor size, n(%) | ||||||||||||||
| ≤1 cm | 53 | 41(73.2) | 12(33.3) | <0.001*‡ | 14 | 15 | 16 | 8 | 0.072 | 17 | 17 | 16 | 3 | 0.178 |
| >1 cm | 39 | 15(26.8) | 24(66.7) | 3 | 15 | 10 | 11 | 7 | 12 | 13 | 7 | |||
*
P < 0.05.
‡
Chi-square test.